Update on the management of chronic eczema: new approaches and emerging treatment options

References

• AbramovitsWAtopic dermatitisJ Am Acad Dermatol200553S86S9315968268
   PubMed Web of Science ®Google Scholar
• WüthrichBClinical aspects, epidemiology, and prognosis of atopic dermatitisAnn Allergy Asthma Immunol19998346447010582732
   PubMed Web of Science ®Google Scholar
• KangKPolsterAMNedorostSTStevensSRCooperKDAtopic DermatitisBologniaJJorizzoJRapiniRDermatologyPhiladelphiaMosby2003199214
   Google Scholar
• PalmerCNIrvineADTerron-KwiatkowskiACommon loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitisNat Genet20063844144616550169
   PubMed Web of Science ®Google Scholar
• BrownSJIrvineADAtopic eczema and the filaggrin storySemin Cutan Med Surg20082712813718620134
   PubMed Web of Science ®Google Scholar
• BrenninkmeijerEELegierseCMSillevis SmittJHLastBFGrootenhuisMABosJDThe course of life of patients with childhood atopic dermatitisPediatr Dermatol200926142219250399
   PubMed Web of Science ®Google Scholar
• SimpsonELAtopic dermatitis: a review of topical treatment optionsCurr Med Res Opin20102663364020070141
   PubMed Web of Science ®Google Scholar
• HonKLChingGKLeungTFChoiCYLeeKKNgPCEstimating emollient usage in patients with eczemaClin Exp Dermatol201035222619489850
   PubMed Web of Science ®Google Scholar
• WirénKNohlgårdCNybergFTreatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trialJ Eur Acad Dermatol Venereol2009231267127219508310
   PubMed Web of Science ®Google Scholar
• SzczepanowskaJReichASzepietowskiJCEmollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative studyPediatr Allergy Immunol20081961461818208463
   PubMed Web of Science ®Google Scholar
• CorkMJBrittonJButlerLYoungSMurphyRKeohaneSGComparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist nurseBr J Dermatol200314958258914510993
   PubMed Web of Science ®Google Scholar
• SpergelJMImmunology and treatment of atopic dermatitisAm J Clin Dermatol2008923324418572974
   PubMed Web of Science ®Google Scholar
• HanifinJMCooperKDHoVCGuidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association “Administrative Regulations for Evidence-Based Clinical Practice Guidelines”J Am Acad Dermatol20045039140414988682
   PubMed Web of Science ®Google Scholar
• ThomasKSArmstrongSAveryARandomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczemaBMJ200232476811923161
   PubMed Web of Science ®Google Scholar
• KantorICookPRCullenSIWillisIGibsonJRStanfieldJWDouble-blind bilateral paired comparison of 0.05% halobetasol propionate cream and its vehicle in patients with chronic atopic dermatitis and other eczematous dermatosesJ Am Acad Dermatol199125118411861757615
   PubMed Web of Science ®Google Scholar
• GuzzoCAWeissJSMogaveroHSA review of two controlled multicenter trials comparing 0.05% halobetasol propionate ointment to its vehicle in the treatment of chronic eczematous dermatosesJ Am Acad Dermatol199125117911831757614
   PubMed Web of Science ®Google Scholar
• MoshangTPrednicarbate emollient cream 0.1% in pediatric patients with atopic dermatitisCutis200168636911480151
   PubMed Web of Science ®Google Scholar
• WilliamsHCEstablished corticosteroid creams should be applied only once daily in patients with atopic dermatitisBMJ2007334127217569936
   PubMed Web of Science ®Google Scholar
• CallenJChamlinSEichenfieldLFA systematic review of the safety of topical therapies for atopic dermatitisBr J Dermatol200715620322117223859
   PubMed Web of Science ®Google Scholar
• EichenfieldLFBasuSCalvareseBTrancikRJEffect of desonide hydrogel 0.05% on the hypothalamic-pituitary-adrenal axis in pediatric subjects with moderate to severe atopic dermatitisPediatr Dermatol20072428929517542883
   PubMed Web of Science ®Google Scholar
• CoureauBBussièresJFTremblaySCushing’s syndrome induced by misuse of moderate- to high-potency topical corticosteroidsAnn Pharmacother2008421903190719017822
   PubMed Web of Science ®Google Scholar
• SchlessingerJMillerBGilbertRDPlottRTVanos Study GroupAn open-label adrenal suppression study of 0.1% fluocinonide cream in pediatric patients with atopic dermatitisArch Dermatol20061421568157217178982
   PubMedGoogle Scholar
• FriedlanderSFHebertAAAllenDBFluticasone Pediatrics Safety Study GroupSafety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 monthsJ Am Acad Dermatol20024638739311862174
   PubMed Web of Science ®Google Scholar
• LuckyAWGroteGDWilliamsJLEffect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitisCutis1997591511539071556
   PubMed Web of Science ®Google Scholar
• Aalto-KorteKTurpeinenMBone mineral density in patients with atopic dermatitisBr J Dermatol19971361721759068726
   PubMed Web of Science ®Google Scholar
• HaeckIMHamdyNATimmer-de MikLLow bone mineral density in adult patients with moderate to severe atopic dermatitisBr J Dermatol20091611248125419673879
   PubMed Web of Science ®Google Scholar
• CharmanCRMorrisADWilliamsHCTopical corticosteroid phobia in patients with atopic eczemaBr J Dermatol200014293193610809850
   PubMed Web of Science ®Google Scholar
• AndersonPCDinulosJGAtopic dermatitis and alternative management strategiesCurr Opin Pediatr2009221131138
   Web of Science ®Google Scholar
• PittMGarsideRSteinKA cost-utility analysis of pimecrolimus vs topical corticosteroids and emollients for the treatment of mild and moderate atopic eczemaBr J Dermatol20061541137114616704646
   PubMed Web of Science ®Google Scholar
• BeckLAThe efficacy and safety of tacrolimus ointment: a clinical reviewJ Am Acad Dermatol2005532 Suppl 2S165S17016021171
   PubMed Web of Science ®Google Scholar
• El-BatawyMMBosseilaMAMashalyHMHafezVSTopical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysisJ Dermatol Sci200954768719303745
   PubMed Web of Science ®Google Scholar
• PallerAEichenfieldLFLeungDYStewartDAppellMA 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patientsJ Am Acad Dermatol200144S4744S57
   Web of Science ®Google Scholar
• HanifinJMLingMRLangleyRBrenemanDRafalETacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacyJ Am Acad Dermatol2001144S28S3811423833
   PubMed Web of Science ®Google Scholar
• SoterNAFleischerABJrWebsterGFMonroeELawrenceITacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safetyJ Am Acad Dermatol2001144S39S4611423833
   PubMed Web of Science ®Google Scholar
• ChapmanMSSchachnerLABrenemanDUS Tacrolimus Ointment Study GroupTacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitisJ Am Acad Dermatol200553S177S18516021173
   PubMed Web of Science ®Google Scholar
• HoegerPHLeeKHJautovaJThe treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trialBr J Dermatol200916041542219067708
   PubMed Web of Science ®Google Scholar
• LangleyRGEichenfieldLFLuckyAWBoguniewiczMBarbierNCherillRSustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitisPediatr Dermatol20082530130718577032
   PubMed Web of Science ®Google Scholar
• KangSLuckyAWPariserDLawrenceIHanifinJMLong-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in childrenJ Am Acad Dermatol200144Suppl 1S58S6411145796
   PubMed Web of Science ®Google Scholar
• ReitamoSWollenbergASchöpfESafety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study GroupArch Dermatol2000136999100610926735
   PubMed Web of Science ®Google Scholar
• ReitamoSRustinMRuzickaTEuropean Tacrolimus Ointment Study GroupEfficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitisJ Allergy Clin Immunol200210954755511898005
   PubMed Web of Science ®Google Scholar
• ReitamoSVan LeentEJHoVEuropean/Canadian Tacrolimus Ointment Study GroupEfficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitisJ Allergy Clin Immunol200210953954611898004
   PubMed Web of Science ®Google Scholar
• ReitamoSHarperJBosJDEuropean Tacrolimus Ointment Group0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trialBr J Dermatol200415055456215030341
   PubMed Web of Science ®Google Scholar
• DossNReitamoSDubertretLSuperiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trialBr J Dermatol200916142743419416227
   PubMed Web of Science ®Google Scholar
• LeungDYHanifinJMPariserDMEffects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trialBr J Dermatol2009161435443 Epub 2009 Mar 30.19416245
   PubMed Web of Science ®Google Scholar
• LugerTALahfaMFölster-HolstRLong-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitisJ Dermatolog Treat20041516917815204150
   PubMedGoogle Scholar
• PallerASEichenfieldLFKirsnerRSShullTJaraczESimpsonELUS Tacrolimus Ointment Study GroupThree times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for usePediatrics2008122e1210e121819015204
   PubMed Web of Science ®Google Scholar
• BrenemanDFleischerABJrAbramovitsWTacrolimus Ointment Study GroupIntermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicleJ Am Acad Dermatol20085899099918359127
   PubMed Web of Science ®Google Scholar
• AbramovitsWFleischerABJrJaraczEBrenemanDAdult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus creamJ Drugs Dermatol200871153115819137769
   PubMedGoogle Scholar
• StanderSStanderHSeelingerSLugerTASteinhoffMTopical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skinBr J Dermatol20071561020102617388925
   PubMed Web of Science ®Google Scholar
• LingMGottliebAPariserDA randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitisJ Dermatolog Treat20051614214816096179
   PubMed Web of Science ®Google Scholar
• BillichAAschauerHAszódiAStuetzAPercutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimusInt J Pharm2004269293514698574
   PubMed Web of Science ®Google Scholar
• BergerTGDuvicMVan VoorheesASVanBeekMJFriedenIJThe use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task ForceJ Am Acad Dermatol20065481882316635663
   PubMed Web of Science ®Google Scholar
• HuiRLLideWChanJSchottingerJYoshinagaMMillaresMAssociation between exposure to topical tacrolimus or pimecrolimus and cancersAnn Pharmacother2009431956196319903860
   PubMed Web of Science ®Google Scholar
• SladeHBFowlerJDraelosZDReeceBTCargillDIClinical efficacy evaluation of a novel barrier protection creamCutis20081082212819202673
   PubMed Web of Science ®Google Scholar
• AbramovitsWPerlmutterAMimyX creamSkinmed20065293016522980
   PubMedGoogle Scholar
• BelloniGPinelliSVeraldiSA randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitisEur J Dermatol200515313615701590
   PubMed Web of Science ®Google Scholar
• AbramovitsWBoguniewiczMAdult Atopiclair Study GroupA multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adultsJ Drugs Dermatol2006523624416573256
   PubMedGoogle Scholar
• PatriziACapitanioBNeriIA double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patientsPediatr Allergy Immunol20081961962518298424
   PubMed Web of Science ®Google Scholar
• BoguniewiczMZeichnerJAEichenfieldLFMAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled studyJ Pediatr200815285485918492531
   PubMed Web of Science ®Google Scholar
• SugarmanJLParishLCEfficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitisJ Drugs Dermatol200981106111120027938
   PubMed Web of Science ®Google Scholar
• EberleinBEickeCReinhardtHWRingJAdjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)J Eur Acad Dermatol Venereol2008122738218705632
   PubMed Web of Science ®Google Scholar
• CaproniMTorchiaDAntigaEThe comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical studyBr J Dermatol20072156312319
   Web of Science ®Google Scholar
• NorrisDAMechanisms of action of topical therapies and the rationale for combination therapyJ Am Acad Dermatol200553S17S2515968260
   PubMed Web of Science ®Google Scholar
• PesericoAStädtlerGSebastianMFernandezRSVickKBieberTReduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled studyBr J Dermatol200815880180718284403
   PubMed Web of Science ®Google Scholar
• TorokHMMaas-IrslingerRSlaytonRMClocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitisCutis20037216116612953943
   PubMed Web of Science ®Google Scholar
• KubotaYYonedaKNakaiKEffect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot studyJ Am Acad Dermatol20096021221719027990
   PubMed Web of Science ®Google Scholar
• OranjeAPDevillersACKunzBTreatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel’s opinion and review of the literatureJ Eur Acad Dermatol Venereol2006201277128617062046
   PubMed Web of Science ®Google Scholar
• HindleyDGallowayGMurrayJGardenerLA randomised study of “wet wraps” versus conventional treatment for atopic eczemaArch Dis Child20069116416816308411
   PubMed Web of Science ®Google Scholar
• PeiAYChanHHHoKMThe effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in childrenPediatr Dermatol20011834334811576413
   PubMed Web of Science ®Google Scholar
• McGowanRTuckerPJosephDShort-term growth and bone turnover in children undergoing occlusive steroid (‘Wet-Wrap’) dressings for treatment of atopic eczemaJ Dermatolog Treat20031414915214522624
   PubMedGoogle Scholar
• Krejci-ManwaringJTusaMGCarrollCStealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitisJ Am Acad Dermatol20075621121617224366
   PubMed Web of Science ®Google Scholar
• MajoieIMOldhoffJMvan WeeldenHNarrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitisJ Am Acad Dermatol200960778419103360
   PubMed Web of Science ®Google Scholar
• JeklerJLarköOPhototherapy for atopic dermatitis with ultraviolet A (UVA), low-dose UVB and combined UVA and UVB: two paired-comparison studiesPhotodermatol Photoimmunol Photomed199181511561814425
   PubMed Web of Science ®Google Scholar
• TzanevaSSeeberASchwaigerMHönigsmannHTanewAHigh-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitisJ Am Acad Dermatol20014550350711568738
   PubMed Web of Science ®Google Scholar
• AbeckDSchmidtTFesqHLong-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitisJ Am Acad Dermatol2000422 Pt 125425710642681
   PubMed Web of Science ®Google Scholar
• Grundmann-KollmannMBehrensSPoddaMPeterRUKaufmannRKerscherMPhototherapy for atopic eczema with narrow-band UVBJ Am Acad Dermatol19994099599710365933
   PubMed Web of Science ®Google Scholar
• ReynoldsNJFranklinVGrayJCDiffeyBLFarrPMNarrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trialLancet20013572012201611438134
   PubMed Web of Science ®Google Scholar
• Der-PetrossianMSeeberAHönigsmannHTanewAHalf-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitisBr J Dermatol2000142394310651692
   PubMed Web of Science ®Google Scholar
• GambichlerTOthlinghausNTomiNSMedium-dose ultraviolet (UV) A1 vs narrowband UVB phototherapy in atopic eczema: a randomized crossover studyBr J Dermatol200916065265819120333
   PubMed Web of Science ®Google Scholar
• KrutmannJDiepgenTLLugerTAHigh-dose UVA1 therapy for atopic dermatitis: results of a multicenter trialJ Am Acad Dermatol1998385895939555799
   PubMed Web of Science ®Google Scholar
• GeorgeSABilslandDJJohnsonBEFergusonJNarrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitisBr J Dermatol199312849568427822
   PubMed Web of Science ®Google Scholar
• SandMBecharaFGSandDExtracorporeal photopheresis as a treatment for patients with severe, refractory atopic dermatitisDermatology200721513413817684376
   PubMed Web of Science ®Google Scholar
• MeduriNBVandergriffTRasmussenHJacobeHPhototherapy in the management of atopic dermatitis: a systematic reviewPhotodermatol Photoimmunol Photomed20072310611217598862
   PubMed Web of Science ®Google Scholar
• GambichlerTBreuckmannFBomsSAltmeyerPKreuterANarrowband UVB phototherapy in skin conditions beyond psoriasisJ Am Acad Dermatol20055266067015793518
   PubMed Web of Science ®Google Scholar
• ten BergeOvan WeeldenHBruijnzeel-KoomenCAde Bruin-WellerMSSigurdssonVThrowing a light on photosensitivity in atopic dermatitis: a retrospective studyAm J Clin Dermatol20091011912319222251
   PubMed Web of Science ®Google Scholar
• WeischerMBlumAEberhardFRöckenMBerneburgMNo evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective studyActa Derm Venereol20048437037415370703
   PubMed Web of Science ®Google Scholar
• SchmittJSchäkelKSchmittNMeurerMSystemic treatment of severe atopic eczema: a systematic reviewActa Derm Venereol20078710011117340015
   PubMed Web of Science ®Google Scholar
• WallingHWGeramiPSontheimerRDJuvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and managementPaediatr Drugs201012233420034339
   PubMedGoogle Scholar
• RicciGDondiAPatriziAMasiMSystemic therapy of atopic dermatitis in childrenDrugs20096929730619275273
   PubMed Web of Science ®Google Scholar
• GalliEChiniLMoscheseVMethylprednisolone bolus: a novel therapy for severe atopic dermatitisActa Paediatr1994833153178038536
   PubMed Web of Science ®Google Scholar
• ForteWCSumitaJMRodriguesAGLiusonDTanakaERebound phenomenon to systemic corticosteroid in atopic dermatitisAllergol Immunopathol (Madr)20053330731116371217
   PubMedGoogle Scholar
• SalekMSFinlayAYLuscombeDKCyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trialBr J Dermatol19931294224308217757
   PubMed Web of Science ®Google Scholar
• SchmittJSchäkelKFölster-HolstRPrednisolone vs ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trialBr J Dermatol20091026 (Epub)
   Google Scholar
• SchmittJSchmittNMeurerMCyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysisJ Eur Acad Dermatol Venereol20072160661917447974
   PubMed Web of Science ®Google Scholar
• PedreiraCCKingEJonesGOral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczemaPediatr Dermatol20072461362018035982
   PubMed Web of Science ®Google Scholar
• GranlundHErkkoPReitamoSLong-term follow-up of eczema patients treated with cyclosporineActa Derm Venereol19987840439498025
   PubMed Web of Science ®Google Scholar
• HijnenDJten BergeOTimmer-de MikLBruijnzeel-KoomenCAde Bruin-WellerMSEfficacy and safety of long-term treatment with cyclosporin A for atopic dermatitisJ Eur Acad Dermatol Venereol200721858917207173
   PubMed Web of Science ®Google Scholar
• WeatherheadSCWahieSReynoldsNJMeggittSJAn open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczemaBr J Dermatol200715634635117223876
   PubMed Web of Science ®Google Scholar
• GoujonCBérardFDahelKMethotrexate for the treatment of adult atopic dermatitisEur J Dermatol20061615515816581567
   PubMed Web of Science ®Google Scholar
• LyakhovitskyABarzilaiAHeymanRLow-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adultsJ Eur Acad Dermatol Venereol201024434919552716
   PubMed Web of Science ®Google Scholar
• ZollerLRamonMBergmanRLow dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczemaIsr Med Assoc J20081041341418669134
   PubMed Web of Science ®Google Scholar
• ShaffraliFCColverGBMessengerAGGawkrodgerDJExperience with low-dose methotrexate for the treatment of eczema in the elderlyJ Am Acad Dermatol20034841741912637922
   PubMed Web of Science ®Google Scholar
• MeggittSJGrayJCReynoldsNJAzathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trialLancet200636783984616530578
   PubMed Web of Science ®Google Scholar
• HughesRCollinsPRogersSFurther experience of using azathioprine in the treatment of severe atopic dermatitisClin Exp Dermatol2008337101118681884
   PubMed Web of Science ®Google Scholar
• MurphyLAAthertonDA retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppressionBr J Dermatol200214730831512174104
   PubMed Web of Science ®Google Scholar
• NeuberKSchwartzIItschertGDieckATTreatment of atopic eczema with oral mycophenolate mofetilBr J Dermatol200014338539110951150
   PubMed Web of Science ®Google Scholar
• Grundmann-KollmannMPoddaMOchsendorfFBoehnckeWHKaufmannRZollnerTMMycophenolate mofetil is effective in the treatment of atopic dermatitisArch Dermatol200113787087311453805
   PubMed Web of Science ®Google Scholar
• MurrayMLCohenJBMycophenolate mofetil therapy for moderate to severe atopic dermatitisClin Exp Dermatol200732232717059445
   PubMed Web of Science ®Google Scholar
• HellerMShinHTOrlowSJSchafferJVMycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patientsBr J Dermatol200715712713217489974
   PubMed Web of Science ®Google Scholar
• WozelGVitézLPfeifferCSevere atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental dataDermatol Online J200633012616638420
   PubMedGoogle Scholar
• SchmittJWozelGPfeifferCLeflunomide as a novel treatment option in severe atopic dermatitisBr J Dermatol20041501182118515214907
   PubMed Web of Science ®Google Scholar
• Van VelsenSGHaeckIMBruijnzeel-KoomenCASevere atopic dermatitis treated with everolimusJ Dermatolog Treat20092036536719954394
   PubMed Web of Science ®Google Scholar
• BremmerMSBremmerSFBaig-LewisSSimpsonELAre biologics safe in the treatment of atopic dermatitis? A review with a focus on immediate hypersensitivity reactionsJ Am Acad Dermatol200961666676 Epub 2009 Jul 31. PMID: 1964677919646779
   PubMed Web of Science ®Google Scholar
• TorreloAHartoASendagortaECzarnetzkiBMLedoAInterferon-alpha therapy in atopic dermatitisActa Derm Venereol1992723703721361287
   PubMed Web of Science ®Google Scholar
• HanifinJMSchneiderLCLeungDYRecombinant interferon gamma therapy for atopic dermatitisJ Am Acad Dermatol1993281891978432915
   PubMed Web of Science ®Google Scholar
• ReinholdUKukelSBrzoskaJKreyselHWSystemic interferon gamma treatment in severe atopic dermatitisJ Am Acad Dermatol19932958638315079
   PubMed Web of Science ®Google Scholar
• SchneiderLCBazZZarconeCZurakowskiDLong-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitisAnn Allergy Asthma Immunol1998802632689532976
   PubMed Web of Science ®Google Scholar
• JangIGYangJKLeeHJClinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gammaJ Am Acad Dermatol2000421033104010827410
   PubMed Web of Science ®Google Scholar
• JullienDNicolasJFFrappazAThivoletJAlpha interferon treatment in atopic dermatitisActa Derm Venereol1993731301328103259
   PubMed Web of Science ®Google Scholar
• NielsenBWReimertCMHammerRSchiøtzPOThestrup-PedersenKInterferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteinsAllergy1994491201287513506
   PubMed Web of Science ®Google Scholar
• NohGWLeeKYBlood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitisAllergy199853120212079930598
   PubMed Web of Science ®Google Scholar
• WakimMAlazardMYajimaASpeightsDSaxonAStiehmERHigh dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndromeAnn Allergy Asthma Immunol1998811531589723561
   PubMed Web of Science ®Google Scholar
• JollesSHughesJRustinMThe treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literatureBr J Dermatol200014255155410735971
   PubMed Web of Science ®Google Scholar
• HuangJLLeeWYChenLCKuoMLHsiehKHChanges of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapyAnn Allergy Asthma Immunol20008434535210752921
   PubMed Web of Science ®Google Scholar
• JollesSA review of high-dose intravenous immunoglobulin treatment for atopic dermatitisClin Exp Dermatol20021273711952664
   PubMed Web of Science ®Google Scholar
• PaulCLahfaMBachelezHChevretSDubertretLA randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitisBr J Dermatol200214751852212207594
   PubMed Web of Science ®Google Scholar
• JollesSSewellCWebsterDAdjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 countsActa Derm Venereol20038343343714690338
   PubMed Web of Science ®Google Scholar
• BemanianMHMovahediMFarhoudiAHigh doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitisIran J Allergy Asthma Immunol2005413914317301437
   PubMedGoogle Scholar
• JacobiAAntoniCMangerBSchulerGHertlMInfliximab in the treatment of moderate to severe atopic dermatitisJ Am Acad Dermatol20055252252615761436
   PubMed Web of Science ®Google Scholar
• RullanPMuraseJTwo cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapyJ Drugs Dermatol2009887387619746681
   PubMed Web of Science ®Google Scholar
• BukaRLReshBRobertsBCunninghamBBFriedlanderSEtanercept is minimally effective in 2 children with atopic dermatitisJ Am Acad Dermatol20055335835916021144
   PubMed Web of Science ®Google Scholar
• EsmailzadehAYousefiPFarhiDPredictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patientsDermatology200921926326719684381
   PubMed Web of Science ®Google Scholar
• MoulDKRouthouskaSBRobinsonMRKormanNJAlefacept for moderate to severe atopic dermatitis: a pilot study in adultsJ Am Acad Dermatol20085898498918395294
   PubMed Web of Science ®Google Scholar
• FlohrCJohanssonSGWahlgrenCFWilliamsHHow atopic is atopic dermatitis?J Allergy Clin Immunol200411415015815241359
   PubMed Web of Science ®Google Scholar
• SheinkopfLERafiAWDoLTKatzRMKlaustermeyerWBEfficacy of omalizumab in the treatment of atopic dermatitis: a pilot studyAllergy Asthma Proc20082953053718926061
   PubMed Web of Science ®Google Scholar
• VigoPGGirgisKRPfuetzeBLCritchlowMEFisherJHussainIEfficacy of anti-IgE therapy in patients with atopic dermatitisJ Am Acad Dermatol20065516817016781320
   PubMed Web of Science ®Google Scholar
• LaneJECheyneyJMLaneTNKentDECohenDJTreatment of recalcitrant atopic dermatitis with omalizumabJ Am Acad Dermatol2006546872 Epub 2005 Nov 28.16384758
   PubMed Web of Science ®Google Scholar
• FormanSBGarrettABSuccess of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor, FcepsilonRICutis200780384017725062
   PubMed Web of Science ®Google Scholar
• KrathenRAHsuSFailure of omalizumab for treatment of severe adult atopic dermatitisJ Am Acad Dermatol20055333834016021135
   PubMed Web of Science ®Google Scholar
• PhippsSFlood-PagePMenzies-GowAOngYEKayABIntravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skinJ Invest Dermatol20041221406141215175031
   PubMed Web of Science ®Google Scholar
• OldhoffJMDarsowUWerfelTAnti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitisAllergy20056069369615813818
   PubMed Web of Science ®Google Scholar
• SimonDHösliSKostylinaGYawalkarNSimonHUAnti-CD20 (rituximab) treatment improves atopic eczemaJ Allergy Clin Immunol200812112212818206507
   PubMed Web of Science ®Google Scholar
• BorchardKLOrchardDSystemic therapy of paediatric atopic dermatitis: an updateAustralas J Dermatol20084912313418638218
   PubMed Web of Science ®Google Scholar
• HermanSMVenderRBAntihistamines in the treatment of dermatitisJ Cutan Med Surg2003746747315926215
   PubMed Web of Science ®Google Scholar
• SimonsFEProspective, long-term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. ETAC Study Group. Early Treatment of the Atopic ChildJ Allergy Clin Immunol19991042 Pt 143344010452767
   PubMed Web of Science ®Google Scholar
• SimonsFEEarly Prevention of Asthma in Atopic Children (EPAAC) Study GroupSafety of levocetirizine treatment in young atopic children: An 18-month studyPediatr Allergy Immunol20071853554217561929
   PubMed Web of Science ®Google Scholar
• MonroeEWRelative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitisClin Ther19921417211349509
   PubMed Web of Science ®Google Scholar
• KawashimaMTangoTNoguchiTInagiMNakagawaHHaradaSAddition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group studyBr J Dermatol20031481212122112828751
   PubMed Web of Science ®Google Scholar
• DiepgenTLEarly Treatment of the Atopic Child Study Group. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 monthsPediatr Allergy Immunol20021327828612390444
   PubMed Web of Science ®Google Scholar
• MundayJBloomfieldRGoldmanMChlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching componentDermatology2002205404512145433
   PubMed Web of Science ®Google Scholar
• Berth-JonesJGraham-BrownRAFailure of terfenadine in relieving the pruritus of atopic dermatitisBr J Dermatol19891216356372574594
   PubMed Web of Science ®Google Scholar
• EhlayelMSBenerASabbahAMontelukast treatment in children with moderately severe atopic dermatitisEur Ann Allergy Clin Immunol20073923223618236999
   PubMedGoogle Scholar
• CapellaGLGrigerioEAltomareGA randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adultsEur J Dermatol20011120921311358726
   PubMed Web of Science ®Google Scholar
• GongJQLinLLinTSkin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trialBr J Dermatol200615568068716965415
   PubMed Web of Science ®Google Scholar
• HuangJTAbramsMTlouganBRademakerAPallerASTreatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severityPediatrics2009123e808e81419403473
   PubMed Web of Science ®Google Scholar
• SyedSWeibelLKennedyHHarperJIA pilot study showing pulsed-dye laser treatment improves localized areas of chronic atopic dermatitisClin Exp Dermatol20083324324818201257
   PubMed Web of Science ®Google Scholar